ataluren sold brand name translarna medication treatment duchenne muscular dystrophy designed ptc therapeutics ataluren used european union treat people duchenne muscular dystrophy nonsense mutation dystrophin gene walk five years people pregnant breast feeding take people taking ataluren clinical trials experienced vomiting experienced diarrhea nausea headache upper abdominal pain flatulence people experienced decreased appetite weight loss high levels triglycerides high blood pressure cough nosebleeds abdominal discomfort constipation rashes pain arms legs chest muscles blood urine urinary incontinence aminoglycosides given someone taking ataluren interfere mechanism action caution used drugs induce substrates large number studies failed identify biological target discovered bind stabilize firefly luciferase thus explaining mechanism created false positive effect read ataluren thought make ribosomes less sensitive premature stop codons effect referred readthrough promoting insertion certain nearcognate trna site nonsense codons apparent effects downstream transcription mrna processing stability mrna resultant protein thereby making functional protein similar nonmutated endogenous seems work particularly well stop codon studies demonstrated ataluren treatment increases expression fulllength dystrophin protein human mouse primary muscle cells containing premature stop codon mutation duchenne muscular dystrophy rescues striated muscle studies mice premature stop codon mutation cystic fibrosis demonstrated increased cftr protein production extending work mechanistic study yeast human cells elucidated details atalurenmediated nonstandard codonanticodon base pairings result specific amino acid substitutions specific codon positions cftr european medicines agency review approval ataluren concluded nonclinical data available considered sufficient support proposed mechanism action alleviate earlier concerns selectivity ataluren premature stop ataluren oxadiazole chemical name ataluren discovered scientists ptc therapeutics collaboration lee sweeneys lab university pennsylvania initially funded part parent project muscular team used phenotypic screening chemical library identify compounds increased amount protein expressed mutated genes optimized one hits screen create results many cellbased screens biological target ataluren phase clinical trials started ptc therapeutics released preliminary results phase iib clinical trial duchenne muscular dystrophy participants showing significant improvement six minute walk distance weeks may ataluren received positive opinion committee medicinal products human use chmp european medicines agency received market authorization european commission treat people nonsense mutation duchenne muscular dystrophy august confirmatory phase iii clinical trial december market germany france italy denmark spain number european union february fda declined accept ptc therapeutics new drug application ataluren based clinical trial ataluren missed primary endpoint ptc appealed fda declined october july nhs england agreed managed access agreement maa translarna providing reimbursed patient access translarna england via fiveyear maa followed positive recommendation national institute health care excellence nice april subject ptc nhs england finalizing terms maa nice issued final guidance later july implementation maa patients following within two march ptc terminated development ataluren cystic fibrosis due lack efficacy phase iii httpsenwikipediaorgwikiataluren